---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-084012"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:34:55.982813+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rein Therapeutics issues $2.875M in unsecured notes to institutional investors at 20% OID

## Summary
- Issued $2.875M aggregate principal notes for $2.3M net cash (20% original issue discount).
- Notes mature 30 days after $10M+ equity raise or by June 30, 2026; no cash interest.
- Private placement to three institutional investors; notes are unsecured general obligations.
- Proceeds for working capital; sold under Section 4(a)(2) and Rule 506 of Regulation D.

## SEC filing metadata
- accession: 0001193125-26-084012
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312526084012/0001193125-26-084012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312526084012/d121919d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-084012
- JSON: https://secwatch.observer/filing/0001193125-26-084012.json
- Plain text: https://secwatch.observer/filing/0001193125-26-084012.txt

## Source-grounded claims
- claim_id: 122dd453942f7d521d74bbd9ad15b9e204bbd690
  claim: Rein Therapeutics, Inc. incurred senior notes of $2,875,000 with three institutional investors at 20% original issue discount maturing the earlier of (i) the date of the closing of the next issuance and sale of securities of the Company, in a single transaction or series of related transactions.
  evidence_excerpt: On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420565/000119312526084012/0001193125-26-084012-index.htm
- claim_id: 1d9bcbb6366c1040c55605929a4c4f8512de5c10
  claim: Rein Therapeutics, Inc. entered into Purchase Agreement with three institutional investors valued at $2,875,000.
  evidence_excerpt: On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420565/000119312526084012/0001193125-26-084012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.